. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):22–29. doi: 10.1097/QAI.0000000000000221

Table 2.

a. Cumulative six-month optimal adherence to ARV and TB medications in all XDR-TB patients (N=104)
TB Medication Adherence	ARV Adherence^*	Dual Adherent^**
70/104 (67.3)	60/68 (88.2)	45/68 (66.2)

b. Cumulative six-month optimal adherence in XDR-TB-HIV Co-infected Patients on both ARV and TB medications (N=68)
XDR-TB Medication Adherence	ARV Adherence
	Optimal Adherence	Sub-optimal Adherence
Optimal Adherence	45	1
Sub-optimal Adherence Sometimes Non-Adherent (%) Often Non-Adherent (%) Always Non-Adherent (%)	15 9 (60.0) 4 (26.7) 2 (13.3)	7 4 (57.1) 3 (42.9) 0
XDR-TB Medication Adherence	46/68 (67.7%)
ARV Adherence	60/68 (88.2%)	p<0.001

75 patients reported being on ARV at six months; 68 provided adherence data

^**

Calculated among HIV infected individuals on ARV with adherence data. Count includes individuals that are dual adherent to both ARVs and TB medications. One patient provided ARV adherence data, but not TB adherence data.